Literature DB >> 16902287

Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis.

H J Bovenschen1, I M J J van Vlijmen-Willems, P C M van de Kerkhof, P E J van Erp.   

Abstract

BACKGROUND: Depletion of CD4+ CD25+ Foxp3+ naturally occurring regulatory T cells (T(reg)) induces autoimmune phenomena. These cells have not yet been fully characterized in the skin of psoriatic patients.
OBJECTIVES: To prove that the Zenon immunofluorescent labeling technique is suitable for the demonstration of co-localization of T-cell markers and in particular to show the distribution of T(reg) in psoriatic skin.
METHODS: In biopsies derived from normal and psoriatic skin, CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+, CD8+ CD45RO+ and CD4+ CD25+ Foxp3+ cells in the dermis and in the epidermis were immunophenotyped, using a quantitative immunofluorescent labeling technique (Zenon), analyzed and compared using image analysis.
RESULTS: The immunofluorescent labeling technique was shown to be an easy and reliable tool to demonstrate co-localization of T-cell markers. In psoriasis, all pathogenic T-cell subsets (CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ CD45RO+ cells) were significantly increased in the dermis and in the epidermis, as compared to normal skin (all p < 0.05). Using this labeling technique we were able to reveal CD4+ CD25+ Foxp3+ T(reg) in psoriatic dermis, but not in the dermis of normal skin (p < 0.0001).
CONCLUSIONS: The Zenon immunofluorescence technique in combination with image analysis is suitable for the demonstration of co-localization of T-cell markers in tissue. Increased numbers of pathogenic T cells (CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ CD45RO+) were shown in the dermis and epidermis, whereas CD4+ CD25+ Foxp3+ T(reg) were identified in psoriatic skin with a predilection for the upper dermis. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902287     DOI: 10.1159/000093849

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  14 in total

Review 1.  Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.

Authors:  Bilikere S Dwarakanath; Abdullah Farooque; Seema Gupta
Journal:  Cancer Rep (Hoboken)       Date:  2018-05-15

2.  Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms.

Authors:  Lauren Y Cao; Jin-Sung Chung; Takahiro Teshima; Lawrence Feigenbaum; Ponciano D Cruz; Heidi T Jacobe; Benjamin F Chong; Kiyoshi Ariizumi
Journal:  J Invest Dermatol       Date:  2016-05-25       Impact factor: 8.551

3.  Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis.

Authors:  Woo-Jin Yun; Deok-Woo Lee; Sung-Eun Chang; Ghil-Suk Yoon; Joo-Ryung Huh; Chong-Hyun Won; Mi-Woo Lee; Sung-Eun Kim; Beom-Joon Kim; Kee-Chan Moon; Jee-Ho Choi
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

Review 4.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

5.  Regulatory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major.

Authors:  Shervin G Hoseini; Shaghayegh H Javanmard; Sayyed H Zarkesh; Ali Khamesipour; Laleh Rafiei; Khadijeh Karbalaie; Mohamadali Nilforoushzade; Mehdi Baghaei; Seyed H Hejazi
Journal:  J Res Med Sci       Date:  2012-06       Impact factor: 1.852

Review 6.  Digestive system in psoriasis: an update.

Authors:  Daniel Pietrzak; Aldona Pietrzak; Dorota Krasowska; Andrzej Borzęcki; Kinga Franciszkiewicz-Pietrzak; Beata Polkowska-Pruszyńska; Maja Baranowska; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2017-09-13       Impact factor: 3.017

7.  Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells.

Authors:  Michel Lecendreux; Guillaume Churlaud; Fabien Pitoiset; Armelle Regnault; Tu Anh Tran; Roland Liblau; David Klatzmann; Michelle Rosenzwajg
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 8.  Cardiometabolic risk in psoriasis: differential effects of biologic agents.

Authors:  Mariana J Kaplan
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  Correlations between psoriasis and inflammatory bowel diseases.

Authors:  Nevena Skroza; Ilaria Proietti; Riccardo Pampena; Giorgio La Viola; Nicoletta Bernardini; Francesca Nicolucci; Ersilia Tolino; Sara Zuber; Valentina Soccodato; Concetta Potenza
Journal:  Biomed Res Int       Date:  2013-07-21       Impact factor: 3.411

Review 10.  Psoriasis and inflammatory bowel disease: links and risks.

Authors:  Christoforos Vlachos; Georgios Gaitanis; Konstantinos H Katsanos; Dimitrios K Christodoulou; Epameinondas Tsianos; Ioannis D Bassukas
Journal:  Psoriasis (Auckl)       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.